The Pat Smullen Charity Race Day in aid of Cancer Trials Ireland
The Pat Smullen race day in aid of Cancer Trials Ireland returns to the Curragh Racecourse on Saturday, 29th August and will include a host of events and activities to raise funds for Cancer Trials Ireland, the leading cancer research trials organisation in Ireland.
The Race that Saves Lives.
Named in tribute to the nine-time Champion Jockey, the Pat Smullen Race Day features the Pat Smullen Charity Race and the Curragh-to-Curragh 100km charity cycle, along with a variety of other events and activities, all aimed at raising funds for Cancer Trials Ireland, Ireland’s leading cancer research trials organisation.
To date, the Pat Smullen Race Day and the Curragh-to-Curragh charity cycle have collectively raised over €1.2m for pancreatic cancer research in Ireland.
Keep an eye on this page for the 2026 call for riders and cyclists!
Curragh To Curragh
About Cancer Trials Ireland
Cancer Trials Ireland are a not for profit registered charity whose aim is to maximise cancer trial access and outcomes to prolong patient lives and expand cancer research in Ireland.
They are the leading cancer research trials organisation in Ireland, working with the foremost Medical, Surgical and Radiation Oncologists, as well as Haematologists and Research Specialists in Ireland. 98% of all cancer treating specialists in Ireland are members of Cancer Trials Ireland.
Cancer Trials Ireland enables, supports and oversees the running of over 100 trials involving thousands of patients. To find out more, please click the link below.
Pictured at the 2025 Pat Smullen Race Day is Frances Crowley, wife of the late champion jockey Pat Smullen, and Angela Clayton-Lea, Chief Executive of Cancer Trials Ireland.
Speaking at the presentation of funds in 2025
Speaking at the presentation, Angela Clayton Lea, Chief Executive Officer of Cancer Trials Ireland said “it is a very exciting time for global researchers who are studying this disease, because we are developing new drugs that can really target the most common mutations in pancreatic cancer. In the next year, Prof Grainne O’Kane is set to open at least two clinical trials targeting specific mutations in the tumour to help provide a precision oncology approach.”
